ROBERT G. BLOCH, M.D., F.A.C.P.; ALFRED S. DOONEIEF, M.D.; ABRAHAM S. BUCHBERG, M.D.; STANLEY SPELLMAN, M.D.
This content is PDF only. Please click on the PDF icon to access.
Since the hydrazine derivatives of isonicotinic acid were first advocated as effective against tuberculosis early in 1952, there has been much serious appraisal of their therapeutic value. Isoniazid already has taken an important place in phthisiotherapy, if only because of the ease of its application and the small expense of the drug. But there is a need for extensive and prolonged clinical experimentation before the encouraging results of scarcely one year can be confirmed. Much of the early publicity campaign in the daily press about the new "miracle drugs" still lingers on, in the minds not only of the public
BLOCH RG, DOONEIEF AS, BUCHBERG AS, et al. THE CLINICAL EFFECT OF ISONIAZID AND IPRONIAZID IN THE TREATMENT OF PULMONARY TUBERCULOSIS*. Ann Intern Med. 1954;40:881–900. doi: https://doi.org/10.7326/0003-4819-40-5-881
Download citation file:
Published: Ann Intern Med. 1954;40(5):881-900.
Infectious Disease, Mycobacterial Infections, Pulmonary Tuberculosis, Pulmonary/Critical Care.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use